• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Relevance of NUTURE Study Findings for Patients, Payers, Providers

Opinion
Video

Important takeaways for patients, payers, and providers are covered by expert faculty.

This is a video synopsis/summary of a Between the Lines featuring Thomas Crawford, M.D.; and Jim Kenney, R.Ph., MBA.

Crawford and Kenney discuss the implications of spinal muscular atrophy therapy studies for patients, providers, and payers. While transformational for a previously fatal pediatric disease, the extremely high costs of these innovative therapies (e.g.,nusinersen costs $125,000 per dose) raises societal questions about equitable access and sustainability.

As more gene and cell therapies emerge for other rare diseases with the potential for significant benefits, balancing innovation incentives and cost management across the healthcare ecosystem will be an ongoing challenge. Payers must rapidly get up to speed on unfamiliar diseases and make coverage decisions with limited long-term data.

Key next steps include continued education and collaboration among all stakeholders — patients, providers, payersand policymakers — will be needed to ensure patient access while supporting further progress.

 

Video synopsis is AI-generated and reviewed by Managed Healthcare Executive® editorial staff.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
© 2024 MJH Life Sciences

All rights reserved.